Perspective Therapeutics, Inc.CATXNYSE
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank49
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P49
Within normal range
vs 2Y Ago
-0.2x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
PeriodValue
Q4 2025-2.44%
Q3 2025-17.79%
Q2 202535.91%
Q1 202518.88%
Q4 2024-890.43%
Q3 2024137.81%
Q2 2024-164.28%
Q1 2024253.73%
Q4 202310.90%
Q3 2023-25.25%
Q2 202316.98%
Q1 2023-236.32%
Q4 2022-63.98%
Q3 202239.02%
Q2 2022-103.31%
Q1 2022-8.30%
Q4 202137.00%
Q3 2021-86.40%
Q2 2021-80.03%
Q1 202118.29%
Q4 2020-124.85%
Q3 202060.14%
Q2 20201.62%
Q1 202032.55%
Q4 2019-95.71%
Q3 201933.71%
Q2 201926.38%
Q1 2019-20.11%
Q4 201830.89%
Q3 2018-11.33%
Q2 2018-34.07%
Q1 201829.09%
Q4 20178.31%
Q3 2017-36.93%
Q2 201718.32%
Q1 201710.60%
Q4 2016-22.76%
Q3 2016-11.98%
Q2 2016-59.86%
Q1 20166.73%